Pharma Pulse: Commercial Risks of the NDC-12 Transition and FDA Approval of Avlayah for Hunter Syndrome

In today’s Pharma Pulse, experts warn of zero-prefix collision risks in the NDC-12 transition, and the FDA grants accelerated approval to Avlayah for Hunter syndrome.